Business Wire

Exasol Announces Expanded Capabilities of Its Analytics SaaS Database, Including ETL Integration

3.5.2022 11:00:00 EEST | Business Wire | Press release

Share

Exasol, the market leading high-performance analytics database, has announced that from today, Exasol SaaS – the scalable, consumption-based SaaS database based on Amazon Web Services (AWS) – now natively interfaces with Keboola, a cloud-based Data Stack as a Service platform. Keboola provides the first complete solution for data engineers, data analysts, and analytics engineers to deliver on the full spectrum of data demands – from data ingestion to automation. Users will benefit from a built-in function that connects them directly to Keboola from Exasol’s SaaS interface. The Keboola low-code platform provides more than 250 integrations for building ETL/ELT and other pipelines, automation, one-click workflows with integrated business case templates, as well as enterprise grade data governance over the entire stack. It’s a combination that provides improved data accuracy and reduces the time to value.

Commenting on the news, Milan Veverka, VP of Alliances at Keboola said: “We believe that by surrounding ourselves with amazing people, we can achieve anything. That's why we focus on building partnerships that matter. Partnerships with companies that have a similar mindset as we do - empowering everyone to make data-driven decisions. Keboola and Exasol provide great solutions together. We built a simple to use, cost-effective and easy to maintain Data Stack as a Service while Exasol provides its fast in-memory database that helps customers to get to their solution. Together we will make both the implementation and the queries themselves much faster for shared customers.”

In addition to the new collaboration with Keboola, Exasol has introduced a series of new product capabilities that expand on its fully managed, SaaS offering. The new product capabilities will further enhance a customer’s ability to access data-led insights quickly, without needing to manage hardware infrastructures. These innovations include:

  • Enhanced AI/ML capabilities: Customers can now solve complex analytics challenges with ease, such as predictive analytics, by bringing in AI/ML algorithms directly to the data. Operationalizing ML models will also bring maximum performance within the database to its users.
  • Data virtualization support: Analysts will be able to access objects from external sources without the need for migrating data. This support will also eliminate the need for the costly management of duplicate data. It will allow users to more easily access their data – whether it’s stored locally or in the cloud – and set-up or create a logical data warehouse.
  • Amazon SageMaker extension: Exasol SaaS now supports a SageMaker Extension, enabling users to develop end-to-end machine learning projects on data stored in Exasol using the Amazon SageMaker Autopilot service. Doing so mean users can turn data into actionable insights in a matter of minutes.

“When it comes to an organization’s data strategy, data leaders are looking for the confidence to modernize with market-proven, enterprise capabilities that offer flexible migration paths – often to the cloud – at a pace and time that fits with budget and resource constraints,” says Donald Kaye, Chief Commercial Officer at Exasol. The impact of this decision can be profound: affecting costs, the pace of innovation, production releases, marketing penetration and security, to name just a few. “To address the complex challenges organizations face when looking to garner actionable insight from their data, we announced, in February, the strengthening of our hybrid cloud proposition by making our high-performance analytics database available via Exasol SaaS.”

Exasol SaaS is available in two versions. The Exasol SaaS Standard Edition delivers industry leading performance on-demand for organizations with smaller data volumes who don’t require advanced analytics and data integration features or extended support. The Exasol SaaS Enterprise Edition is designed for organizations that require multi-departmental analytics environments, need to perform ML or AI in the database, or have complex requirements in terms of data integration and data virtualization.

Both versions of Exasol SaaS are available here.

About Exasol

Exasol was founded in 2000 with the vision to transform how organizations use data. Today, Exasol’s analytics database – the fastest in the world – is trusted by the world’s most ambitious organizations. With offices in several locations across the US and Europe, Exasol is committed to delivering flexible, scalable and powerful analytics solutions to customers wherever they are, in the cloud – public or private - or on-premises.

Exasol – the leading Performance Analytics Database powering insights from the world’s data.

Learn more at: www.exasol.com and follow us on social media: LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Isabella Alder, EMEA PR Manager at Exasol

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 16:15:00 EEST | Press release

OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leading AI providers, including Anthropic, Google, OpenAI, xAI, and DeepSeek, among others. The platform is used by over 8 million global users, including AI-native startups and large enterprises,

Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 16:00:00 EEST | Press release

Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in markets traditional channels can't reach. Each operates at the center of how games are discovered, adopted, an

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release

ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally

BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release

BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye